Cummins Behavioral Health Systems Inc is a licensed substance use treatment provider in Indianapolis, IN, listed in the SAMHSA treatment directory. An intensive outpatient program lets clients attend structured treatment several days a week while living at home. Buprenorphine (Suboxone) is offered to reduce opioid cravings and lower relapse and overdose risk. Naltrexone is used to support recovery from opioid or alcohol use disorder. The program treats co-occurring mental health conditions alongside addiction. The facility reports accepting Medicaid. Private health insurance is accepted. It serves children/adolescents, young adults, adults.
Availability and current services change often. Call (888) 470-5244
and we will help you confirm openings, insurance, and next steps.
Levels of care
OutpatientIntensive outpatient treatmentOutpatient methadone/buprenorphine or naltrexone treatmentRegular outpatient treatment
Type of care
Substance use treatmentTreatment for co-occurring disorders plus serious mental illness (SMI) in adultsTreatment for co-occurring disorders plus serious emotional disturbance (SED) in children
Medications
Buprenorphine used in TreatmentNaltrexone used in Treatment
Payment accepted
Federal, or any government funding for substance use treatment programsIHS/Tribal/Urban (ITU) fundsMedicareMedicaidFederal military insurance (e.g., TRICARE)Private health insuranceCash or self-paymentSAMHSA funding/block grants
Ages served
Children/AdolescentsYoung AdultsAdultsSeniors
Accreditation
State substance use treatment agencyState mental health departmentThe Joint Commission
Free & confidential, 24/7
Not sure which program fits? Talk it through with someone who can help.
Hospital inpatient/24-hour hospital inpatientOutpatientHospital inpatient detoxificationFederal, or any government funding for substance use treatment programsMedicare
3400 Lafayette Road, Suite 200, Indianapolis, IN 46222
OutpatientOutpatient methadone/buprenorphine or naltrexone treatmentRegular outpatient treatmentFederal, or any government funding for substance use treatment programsMedicare